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ABSTRACT
Canine lymphoma is one of the most common haematological neoplasms. Results of a numerous studies 
indicate the important role of chronic inflammation in the development of cancer. The aim of this study was 
to determine the concentrations of novel inflammatory biomarkers in canine lymphoma. Fifteen dogs with 
lymphoma and 15 healthy dogs (control group) participated in this study. The plasma levels of high sensitivity 
C reactive protein (hs CRP), interleukin-6 (IL-6), high mobility group box-1 (HMGB-1), soluble intercellular 
adhesive molecule -1 (sICAM-1), plasminogen activator inhibitor -1 (PAI-1) and soluble urokinase receptor 
of plasminogen activator (suPAR) were measured using canine specific enzyme-linked immunosorbent assay 
(ELISA). Lactate dehydrogenase activity (LDH) was measured using a spectrophotometric method. Dogs with 
lymphoma had significantly increased plasma hsCRP, IL-6, HMBG-1, sICAM-1, and LDH compared with 
the control group. In addition, hsCRP, IL-6, HMBG-1, and suPAR concentrations and LDH activity showed a 
significant strong positive correlation in the lymphoma group. The data obtained support the role of cytokine-
mediated inflammation in canine lymphoma, and suggest the possibility that anti-inflammatory therapies might 
provide a supportive effect. The significant and strong positive correlation between the established (hsCRP, 
IL-6) and novel (HMGB-1, suPAR) inflammatory biomarkers indicate their potential usefulness in canine 
lymphoma diagnostics. 
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Introduction 
Canine lymphoma is one of the most common haematological neoplasms and is 
similar to human non-Hodgkin’s lymphoma (NHL) (TESKE, 1994; STERENCZAK et 
al., 2010). The frequency of canine lymphoma among haematopoietic malignancies is 
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approximately 83% (VAIL et al., 2013). The symptoms of lymphoma are nonspecific 
and highly variable. Inflammation is a very common condition incorporated in all types 
of disease. It represents one of the risk factors of lymphoma development and predicts 
a worse treatment response and survival (EKSTRÖM et al., 2006; BENDE et al. 2009; 
SHARMA et al. 2009). 
As is well-known, inflammation is associated with elevated plasma inflammatory 
markers, C-reactive protein (CRP, hsCRP) and interleukin 6 (IL-6). Novel markers such 
as high mobility group box-1 (HMGB-1), soluble intercellular adhesive molecule -1 
(sICAM-1), plasminogen activator inhibitor -1 (PAI-1) and soluble urokinase receptor 
of plasminogen activator (suPAR) are still under-investigated, especially in the area of 
veterinary medicine.
C-reactive protein (CRP) is the most widely used acute-phase protein in dogs, as well 
as in humans (ISHIDA et al., 2011). In numerous studies of lymphoma, elevated CRP 
has been reported (HERISHANU et al., 2007; MERLO et al., 2007). CRP concentration 
in blood represents a prognostic factor in aggressive NHL in humans. It is also a useful 
biomarker in determining complete remission status after treatment with cytotoxic drugs 
in dogs (HERISHANU et al., 2007; NIELSEN et al., 2007).
Interleukin (IL)-6 is a pleiotropic, pro- and anti-inflammatory cytokine with a broad 
range of humoral and cellular immune effects, related to inflammation, host defence, and 
tissue injury. (RIDKER et al.; 2000 JONES et al., 2001). It is a major inducer of CRP 
synthesis in the liver (BAUMANN and GAULDIE, 1994). In lymphoma, IL-6 is also 
produced and secreted by the lymphoma cells (HERISHANU et al., 2007; BARTSCH et 
al., 2006). This cytokine has a dual role in the regulation of malignancy, being able both 
to promote and to prevent lymphoma cell development (GILBERT and HERMANN, 
2012; LIN et al., 2013). 
High mobility group box -1 (HMGB-1) is a highly conserved nuclear protein 
and a relatively novel inflammatory cytokine proposed to be a new canine marker of 
inflammation (BREZNICEANU et al., 2003; FIUZA et al., 2003; ISHIDA et al., 2011). It 
is secreted into the blood by activated monocytes and macrophages, or is released from 
necrotic cells (LOTZE and TRACEY, 2005; ELLERMAN et al., 2007). This protein has 
an intra- and extracellular role, that promotes access to transcriptional protein assemblies 
on specific nuclear targets. Furthermore, it functions as an extracellular molecule in 
inflammatory conditions and in tumor metastasis. In the circulation, HMGB-1 acts 
as a ‘danger signal’, triggers inflammation and stimulates IL-6 secretion, while high 
concentrations of HMBG-1 promote some tumor cell growth because of its anti-apoptotic 
properties (BREZNICEANU et al., 2003; IVANOV et al., 2007; ISHIDA et al., 2011; 
GUO et al., 2013). 
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The intercellular adhesion molecule (ICAM) belongs to the group of cell adhesion 
molecules. It is upregulated in response to different inflammatory stimuli (FIUZA et al., 
2003; ROSETTE et al., 2005; BRAKE et al., 2006). Originally described as an adhesive 
protein, it is now well-accepted that ICAM is able to transduce biochemical signals, and its 
soluble form is considered as one of the prototypic markers of inflammation (HOLLAND 
and OWENS, 1997; BRAKE et al., 2006). High concentrations of sICAM-1 are found in 
human lymphoma, and are identified as a predictor of poor outcome (TEROL et al., 2003; 
UCHIHARA et al., 2006; ABDELRAZIK et al., 2008). To the best of our knowledge, no 
data are available for canine lymphoma. 
Disturbances of blood coagulation are one of the most frequent complications in 
human malignant lymphoma (WADA et al., 2005). Plasminogen, the plasmin enzyme 
system, is the primary fibrinolytic pathway responsible for vascular homeostasis. 
The urokinase-type plasminogen activator (uPA), when bound to its cellular receptor 
(uPAR), converts inactive plasminogen into active serine protease plasmin (BEVAN and 
MALA, 2008). The main inhibitor of plasmin generation is the plasminogen activator 
inhibitor (PAI-1). This binds to the uPA-uPAR complex on the cell surface, resulting in 
internalization of the complex (BEVAN and MALA, 2008). Changes in the fibrinolytic 
pathway play an important role in lymphoma cell proliferation, invasion and prognosis 
in humans (ZHANG et al., 2006). However, this system has scarcely been investigated 
in canine medicine, and so far there are no data on canine lymphoma regarding those 
fibrinolytic inhibitors. 
LDH activity is one of the components of the International Prognostic Index in human 
lymphoma, and is also an important parameter in the evaluation of canine lymphoma 
patients (DIMOPOULOS et al., 1991; SHIPP, 1994; ZHOU et al., 2005; MAZHER et 
al., 2010).
There have been few or no reports concerning the novel inflammatory and fibrinolytic 
markers in canine medicine. The aim of this study was to determine the concentrations 
of some novel inflammatory markers and indicators of fibrinolytic activity (ICAM-1, 
HMGB-1, PAI-1 and suPAR), and their relationship to established markers. In addition, 
their concentrations were compared to those in healthy dogs in order to demonstrate 
whether these biomarkers could serve as inflammatory and fibrinolytic indicators in 
canine lymphoma patients. 
Materials and methods
Animals. The lymphoma group (L) consisted of 15 dogs with confirmed malignant 
multicentric lymphoma, patients at the Clinic for Internal Diseases of the Faculty of 
Veterinary Medicine, University of Zagreb, Croatia. 
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The dogs were aged between 2 and 13 years, of various breeds (1 Golden Retriever, 1 
Beauceron, 1 Rottweiler, 1 Irish Setter, 1 Beagle, 1 Bernese Mountain Dog, 1 St. Bernard 
Dog, 1 Dogue de Bordeaux, 2 American Stafford Terriers, 5 mix breed) and gender (10 
males and 5 females). All the dogs were evaluated by clinical examination including 
lymph nodes measurement, haematology analysis (CBC and blood smear examination), 
biochemistry analysis and urinalysis. 
Lymphoma was confirmed on the basis of cytological examination by fine-needle 
aspiration of enlarged lymph nodes. Lymph node extirpation and histological confirmation 
of diagnosis were needed in 2 cases. After confirmation of diagnosis, X-ray and ultrasound 
were performed of the thoracic and abdominal cavity for staging purposes. The dogs were 
staged, sub - staged and classified according to the modificated WHO system (six dogs 
were classified as stage IIIb and nine dogs as stage IVb/V). The group of lymphoma 
patients was further divided according to LDH activity into: L1 subgroup with high LDH 
activity (>200 IU/L) and L2 subgroup with normal LDH activity (<200 IU/L).
The control group (C) consisted of 15 healthy dogs: 3 Golden Retrievers, 1 Irish 
Setter, 1 German Shepherd, and 10 mixed breed, 7 males and 8 females. These dogs were 
presented at the Clinic for routine health control. The dogs were deemed healthy based 
on their history, physical and laboratory data (complete blood count, serum biochemistry, 
and urinalysis).
The study protocol was approved by the Ethics Committee for Animal Experimentation 
of the Faculty of Veterinary Medicine, University of Zagreb, Croatia.
Blood analyses. lood from each dog was drawn from the cephalic vein into one EDTA 
vial and one plain vial, with clot activator and separation gel (Vacutainer blood collection 
system; Becton, Dickinson and Co., Rutherford, New Jersey 07070, USA).
Blood from the EDTA vial and sera from the plain vial (obtained by centrifugation 
3000× g for 10 min) was promptly analysed for haematological analysis and routine 
biochemistry panel. Afterwards, plasma from the EDTA vial was separated from blood 
cells by centrifugation at 1200g for 15 min, transferred to -80 °C within 1 hour of 
collection, and stored until analysis. 
Red blood cell count (RBC), white blood cell count (WBC), haemoglobin 
concentration (HB), mean corpuscular volume (MCV), mean corpuscular haemoglobin 
concentration (MCHC) and red cell distribution width (RDW) were evaluated using an 
automatic blood cell counter, “Horiba ABX’’ (Diagnostics, Montpellier, France) and the 
original manufacturer’s reagents. Blood cell morphology and WBC differential count 
were evaluated in Wright stained blood films.
Concentration of blood urea nitrogen (BUN), creatinine (CRE), total protein (TP), 
albumin (ALB), bilirubin (BILI), glucose (GLUC), alanine aminotransferase (ALT), 
aspartate aminotransferase (AST), gamma alkaline phosphatase (ALP), glutamyl 
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transferase (GGT), lactate dehydrogenase (LDH) and calcium (Ca) were measured in 
sera samples using the standard spectrophotometric methods in an Olympus AU600 
biochemical auto analyser (Olympus Corporation, Tokyo, Japan) and using the original 
reagents of the manufacturer (Olympus, Diagnostica GMBH, Hamburg, Germany). 
Concentrations of hsCRP, IL-6, HMGB-1, sICAM-1, PAI-1 and suPAR were 
determined in plasma samples by an ELISA canine test kit (Biotang Source International, 
Camarillo, USA), following the manufacturer’s instructions. The optical density was 
measured with a microplate reader at 450 nm (BioTek Instruments, Vermont, USA). 
Results are given in pg/mL or ng/mL. 
Statistics. The normality of distribution of all variables was tested by the Kolmogorov-
Smirnov test. Differences between lymphoma and healthy dogs were tested either by 
the t test or the Mann-Whitney U test, depending on distribution. Associations between 
variables were tested with Spearman′s correlation coefficient. Statistical analyses were 
performed with computer software (Statistica for Windows, StatSoft Inc.), with the level 
of significance set at P<0.05.
Results
All the measured markers were in the range of assay detection. The concentrations 
of the measured markers and the results of comparison of groups L and C are shown in 
Table 1. 
Table 1. hsCRP, IL-6, HMBG-1, sICAM-1, PAI-1 and suPAR concentrations in dogs with lymphoma 
(L, n = 15) and control healthy dogs (C, n = 15) 
Mean Median Min Max SD P (L:C)
hsCRP   L 4.6 4.7 2.9 7.8 1.2 0.015*
(pg/mL)   C 3.5 3.4 1.5 5.5 1.1
IL-6     L 292 271 235 569 71.2 0.0002*
(pg/mL)   C 212 217 132 273 41.2
HMGB-1 L 94.4 86.1 42.4 224 45.6 0.048*
(pg/mL)   C 71.3 74.0 40.9 93.5 14.1
sICAM-1 L 389 403 310 485 51.0 0.0001*
(pg/mL)   C 307 321 190 370 50.6
PAI-1   L 72.5 64.2 38.6 172 38.3 0.618
(pg/mL)   C 68.5 60.4 25.9 134 34.6
suPAR   L 2499 2341 1796 4204 640 0.992
(pg/mL)   C 2501 2559 1905 2960 323
LDH    L 287 74 41 1304 415 0.002*
(IU/L)    C 48.6 47.0 19.0 83.0 19.1
*P<0,05 for L compared with C (L:C)
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The concentrations of plasma hsCRP, IL-6, HMGB-1, sICAM-1 and LDH activity in 
dogs with lymphoma (L) were significantly higher than those in the healthy controls (C). 
Although slightly increased in lymphoma, PAI-1 and suPAR concentrations did not differ 
significantly from those in the healthy population. The results of comparison according to 
LDH activity between all patients included (L group) and the L1 and L2 subgroups versus 
the control group are shown in Fig 1-7. 
Fig. 1. LDH activity in the lymphoma group (L) and the control (C) group. 
*if P<0.05 for L, L1 and L2 compared with C
Dogs with lymphoma showed significantly higher LDH activity than healthy dogs 
(P<0.002). The subgroup of patients with high LDH activity (L1) showed significantly 
increased hsCRP (P<0.019) and HMBG-1 (P<0.003) compared to the control dogs, while 
the subgroup of patients with normal LDH activity (L2) did not show such a difference. In 
both the subgroups, L1 and L2, sICAM-1 and IL-6 were significantly elevated.
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Fig. 2. hsCRP concentrations in the lymphoma group (L), high LDH activity subgroup (L1), 
normal LDH activity subgroup (L2) and control (C) group 
*if P<0.05 for L, L1 and L2 compared with C 
Fig. 3. IL-6 concentrations in the lymphoma group (L), high LDH activity subgroup (L1), normal 
LDH activity subgroup (L2) and control (C) group 
*if P<0.05 for L, L1 and L2 compared with C
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Fig. 4. HMGB-1 concentrations in the lymphoma group (L), high LDH activity subgroup (L1), 
normal LDH activity subgroup (L2) and control (C) group 
*if P<0.05 for L, L1 and L2 compared with C
Fig. 5. sICAM concentrations in the lymphoma group (L), high LDH activity subgroup (L1), 
normal LDH activity subgroup (L2) and control (C) group 
*if P<0.05 for L, L1 and L2 compared with C
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Fig. 6. PAI 1 concentrations in the lymphoma group (L), high LDH activity subgroup (L1), 
normal LDH activity subgroup (L2) and control (C) group 
Fig. 7. suPAR concentrations in the lymphoma group (L), high LDH activity subgroup (L1), 
normal LDH activity subgroup (L2) and control (C) group 
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The correlation between markers measured is shown in Table 2. 
Table 2. Correlation between inflammatory markers (r) 
hsCRP IL-6 HMGB-1 ICAM-1 PAI-1 suPAR LDH
hsCRP 1.00 0.82* 0.76* -0.07 0.65* 0.85* 0.86
IL-6 0.82* 1.00 0.81* 0.33 0.82* 0.75* 0.96*
HMGB-1 0.76* 0.81* 1.00 0.05 0.64* 0.76* 0.81*
sICAM-1 -0.07 0.33 0.05 1.00 0.41 -0.01 0.32
PAI-1 0.67* 0.82* 0.64* 0.41 1.00 0.64* 0.89*
suPAR 0.85* 0.75* 0.76* -0.01 0.64* 1.00 0.84*
LDH 0.86* 0.96* 0.81* 0.32 0.89* 0.84* 1.00
*P<0.05 
As shown in Table 2, concentrations of hsCRP, IL-6, HMGB-1, PAI-1, suPAR, 
and LDH were significantly positively correlated (P<0.05). There was no significant 
correlation between sICAM-1 and other biomarkers. A significant, medium strength, 
positive correlation (r = 0.50-0.75) was detected between HMBG-1 and PAI-1, hsCRP 
and suPAR. A significant, strong, positive correlation (r = 0.75-1.00) was present between 
all the other measured markers. 
Discussion
Lymphoma is one of the most common tumours in dogs. It is a spontaneous disease, 
characterized by malignant lymphoid cell proliferation (VIEIRA et al., 2010, VAIL et 
al., 2013). Various similarities in the presentation and biology of numerous canine and 
human diseases, including cancer, suggest that similar mechanisms are involved in the 
respective pathogenic events. The clinical presentation and biological behaviour of 
canine lymphoma closely resemble the human disease (BEUING et al., 2008; NADELLA 
et al., 2008). Among the various tumour properties, inflammation is accepted as one of 
the common features. (MANTOVANI, 2008). Results of an increasing number of studies 
indicate the very important role of chronic inflammation for the development of cancer 
(COUSSENS and WERB, 2002). 
C-reactive protein is the most sensitive acute-phase protein in dogs (CERON 
et al., 2005; NIELSEN et al., 2007). In the present study, the concentration of hsCRP 
was significantly higher in dogs with lymphoma when compared with the control 
group (P<0.01). This is in agreement with previous reports in dogs and humans. CRP 
concentrations were increased in dogs with neoplastic lymphatic disorders (MISCHKE 
and ECKERSALL, 2005; MERLO et al., 2007). CRP concentrations were higher 
in non-Hodgkin lymphoma in humans compared with the concentrations in healthy 
individuals (HERISHANU et al., 2007). In addition, many authors agreed that CRP may 
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be considered as a valuable, additional prognostic marker of NHL and diffuse large B cell 
type lymphoma in humans (LEGOUFFE et al., 1998; CAO et al., 2012). IL-6 modulates 
the transcription of liver-specific genes for CRP and determines the hepatic production 
of this acute phase protein in inflammatory conditions (RIDKER et al., 2000; BARTSCH 
et al., 2006; HERISHANU et al., 2007), so we concluded that high CRP concentrations 
reflect elevated serum IL-6 in the investigated dogs. 
In general, IL-6 plays a major role in inflammatory processes and in the development 
and growth of neoplasms. It was found that it is produced by lymphoblastic cell lines 
(EMILIE et al., 1992). Earlier studies have suggested that IL-6 is involved in the 
pathogenesis of human lymphoma and that this cytokine may be useful as an indicator for 
assessing prognosis and drug therapy (KURZROCK et al., 1993; CHOPRA et al., 2004; 
BARTSCH et al., 2006; MOMOI et al., 2013) Increased serum IL-6 in diffuse large B-cell 
human lymphomas was found to be associated with poor prognosis (BARTSCH et al., 
2006). The results from our measurements showed that plasma IL-6 concentrations were 
significantly higher in dogs with lymphoma when compared to the healthy population 
of dogs (P<0.0002). Elevated IL-6 concentrations support the existence of a pro-
inflammatory status in canine lymphoma, but it is not clear whether this is a one of the 
risk factors for lymphoma development, or the consequence of the pathological process 
during the disease. 
HMGB-1 represents one of the novel markers of inflammation in humans as well as 
in veterinary medicine. Many features of tumors have been associated with alterations 
in HMGB-1 location, abundance or plasma concentrations (TANG et al., 2010). The 
lymphoma development in both species, humans and canines, is characterised by 
similar HMGB-related mechanisms (ROVERE-QUERINI et al., 2004; ARDOIN and 
PISETSKY, 2008). In our study, HMBG-1 concentrations were significantly higher in the 
lymphoma group when compared to healthy dogs (P<0.048). This high-mobility protein, 
also known as the damage-associated molecular pattern molecule (DAMP) has been 
previously described in the literature as being elevated in human lymphoma. In addition, 
lymph nodes in lymphoma were found to overexpress HMGB-1 mRNA (TANG et al., 
2010; DEJEAN et al., 2012; MAO et al., 2012). 
According to FIUZA et al. (2003) HMGB-1 is released actively from the nucleus by 
innate immune cells, or passively by necrotic cells. Therefore, both mechanisms could be 
present in dogs with lymphoma. Although the vast majority of papers describe HMGB as 
a proinflammatory protein, its role is not yet fully understood. Namely, a part of a protein 
called A box has a contrary, strong anti-inflammatory activity. Another paradoxical effect 
of HMBG-1 concerns its effect on tumour cells, where this protein promotes both tumour 
neoangiogenesis and also triggers a protective T cell response (TANG et al., 2010).
In the present study, concentrations of another novel marker, sICAM-1, were 
significantly higher in the lymphoma groups (P<0.0001), in comparison to the control 
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group of dogs. These results are in agreement with previous reports for human 
lymphoma (UCHIHARA et al., 2006; ABDELRAZIK et al. 2008). Elevated serum 
ICAM concentrations in humans were found to correlate with stage, disease activity, 
poor response to treatment and to poor survival. Constitutively expressed ICAM-1 is a 
characteristic feature of lymphoma cells in lymph node biopsy samples from patients 
with Hodgkin type disease (UCHIHARA et a., 2006). It is suggested that at least a 
some of the serum ICAM-1 in childhood lymphoma patients probably originates from 
tumor cells (TACYILDIZ et al., 1999). Intracellular CAM has an important role in 
the immune response against tumor cells by mediating the T cell cytotoxic response. 
Namely, ICAM-1-stimulated antitumour immunity is able to overcome tumour-mediated 
immunosuppression in lymphoma (JANEWAY et al., 2001; KANWAR et al., 2003). In 
response to the interaction of IL-6 with its receptor, endothelial cells up-regulate ICAM-
1 expression (CHEUNG et al., 2012; LIN et al., 2013). IL-6 induced expression of 
ICAM-1 and shedding of the soluble part of the molecule by tumour or normal cells. It 
may be responsible for the significant increase in ICAM-1 plasma concentrations in our 
examined dogs. Similar to humans, sICAM could have a role in antitumour activity in 
the circulation of dogs with lymphoma. The plasma concentration of sICAM-1 in dogs 
with lymphoma indicates an activated endothelium and might represent an additional 
biomarker for diagnostic use in veterinary practice. 
Haemostatic disturbances with hypercoagulability are commonly detected in 
both human and canine cancer patients (ANDERSSON et al., 2000). Activation of the 
fibrinolytic system during human lymphoma progression is a well-documented clinical 
phenomenon (HUBER et al., 1993) so we hypothesized that fibrinolytic pathways 
may have a role in canine lymphoma. We measured uPA system activity by the plasma 
concentration of the main inhibitor of plasminogen activator, PAI-1, and its soluble 
receptor, suPAR. They were both increased in dogs with lymphoma, but not significantly. 
Probably due to the small sample size, some differences may not have been detected. The 
soluble form of urokinase-type plasminogen activator receptor (suPAR) is recognized as 
a new inflammatory marker in human medicine, while there are no data on this protein 
in dogs. Concentrations of suPAR in the blood have been found to correlate positively 
with the activation of the immune system. In human medicine, elevated concentrations 
of uPA and/or PAI-1 in tumour tissue extracts are associated with increased tumour 
aggressiveness and poor patient outcome (WADA et al., 2005). Specific blockade of 
plasminogen represents a promising approach for the regulation of T-cell lymphoma 
growth (ISHIHARA et al., 2012). The levels of plasma uPA, uPAR and PAI-1 were found 
to be significantly higher in humans with lymphoma than in a control group (ZHANG et 
al., 2006). In contrast, investigating molecular markers of coagulation and fibrinolysis in 
patients with malignant diseases, ZHOU et al. (2008) found that PAI-1 concentrations 
were not significantly higher in lymphoma patients than in a control group. Chromosomal 
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translocations in leukemia and lymphoma cells did not result in elevated expression of 
PAI-1 and uPAR, suggesting that the uPA system was not altered in these cells. Instead 
of PAI-1, the authors found highly increased expression of the second isoform of PAI, 
PAI-2, in cells with translocations (KASYAPA et al., 2006). Inhibitors and receptors of 
plasminogen activator as part of the fibrinolytic pathways may have a role in canine 
lymphoma, but this still needs to be confirmed in a larger number of animals. 
Serum LDH activity is a useful prognostic marker in haematological malignancies and 
a strong predictor of disease progression and survival rate in human Hodgkin’s lymphoma 
(DIMOPOULOS et al., 1991; SHIPP et al., 1994; ZHOU et al., 2005; MAZHER et al., 
2010). In patients with NHL, LDH activity is one of the components of the International 
Prognostic Index. Dogs with lymphoma showed significantly higher LDH activity than 
healthy dogs (P<0.002). LDH activity is higher when lymphocytes are dividing or when 
cells are distressed or damaged (MAZHER et al., 2010). Taking these features of LDH 
together, we divided lymphoma dogs into two subgroups: one with high LDH activity 
(L1) and the other with normal LDH activity (L2). The group of lymphoma dogs with 
high LDH activity showed significantly increased hsCRP (P<0.019) and HMBG-1 
(P<0.003) compared to the control dogs, while lymphoma dogs with normal LDH activity 
did not show such a difference. sICAM-1 and IL-6 were significantly elevated in the 
both subgroups compared with healthy controls, so we may conclude that elevated LDH 
activity may be connected to a stronger inflammatory process. Concentrations of hsCRP, 
IL-6, HMBG-1, suPAR and LDH activity showed significant, strong (P<0.05, r>0.75) 
and positive correlations in the lymphoma group, indicating the possible usefulness of 
the novel biomarkers of inflammation proposed in the diagnosis of the inflammatory 
state in canine medicine. The correlation between IL-6 concentration and LDH activity 
was remarkably high (0.96), so it would be useful to investigate, in a greater number 
of animals, whether this enzyme could be an indicator of inflammatory status in canine 
lymphoma. 
Conclusion 
Data obtained in this study support the role of cytokine-mediated inflammation in 
canine lymphoma and the possibility that anti-inflammatory therapies might provide a 
supportive effect. However, the reverse causality of lymphoma and inflammation cannot 
be excluded, meaning that inflammation, as a risk factor, may in fact be causing the 
increase in lymphoma incidence. Nevertheless, the strong positive correlation between 
the established (CRP, IL-6) and novel (HMGB-1, suPAR) inflammatory biomarkers 
suggest their potential in canine diagnostics. Whether concentrations of the investigated 
biomarkers can be used to assess the invasive potential and prognosis in dogs with 
lymphoma, as is the case in humans, has to be investigated in further studies. 
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SAŽETAK
Limfom je najčešći hematopoetski tumor u pasa. Brojna istraživanja potvrđuju važnu ulogu upale, napose 
kronične, u razvoju ove, ali i drugih malignih bolesti te je cilj ovoga rada bio odrediti koncentraciju novijih 
markera upale u plazmi pasa oboljelih od limfoma. U istraživanje je bilo uključeno 15 oboljelih pasa i 15 
pasa koji su činili kontrolnu skupinu. Određena je koncentracija C-reaktivnog proteina (hsCRP), interleukina 
6 (IL-6), proteina visoke pokretljivosti grupe 1 (HMGB-1), solubilne intercelularne adhezijske molekule 1 
(sICAM-1), inhibitora aktivatora plazminogena 1 (PAI-1), solubilnog receptora urokinaznog aktivatora 
plazminogena (suPAR) i aktivnosti laktat-dehidrogenaze (LDH). Pretrage za sve navedene pokazatelje učinjene 
su imunoenzimnim testom, osim laktat-dehidrogenaze čija je aktivnost određena spektrofotometrijski. Utvrđeno 
je da psi oboljeli od limfoma imaju statistički značajno povišenu koncentraciju hsCRP-a, IL-6, HMBG-
1, sICAM-1 te LDH u plazmi u odnosu na kontrolnu skupinu. Rezultati potvrđuju ulogu upale posredovane 
citokinima u patogenezi limfoma u pasa, a to zatim upućuje na mogućnost uključivanja protuupalnih lijekova 
u terapijske protokole kod ove bolesti. Nadalje, jaka pozitivna korelacija između CRP-a i IL-6 te HMGB-1 i 
suPAR kao novih pokazatelja upućuje na potencijalnu mogućnost njihova korištenja u dijagnostičke svrhe.
Ključne riječi: upala; fibrinoliza; limfom; pas________________________________________________________________________________________
